Viatris

Viatris is a global generics and specialty pharmaceutical company formed from the merger of Mylan and Pfizer's Upjohn unit, with a broad portfolio of off-patent branded drugs and generics sold worldwide. Its scale in generics gives it wide reach, but the business faces persistent pricing pressure, integration challenges and a heavy debt load inherited from its formation. Viatris pays a dividend with only a few years of history, reflecting a payout that was established after the merger rather than a long track record. The yield is moderate but the low dividend score signals a weaker overall profile, weighed down by debt and uneven earnings. This is best viewed as a turnaround-and-income situation carrying meaningful risk rather than a dependable payer.